Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019042391) APPLICATION OF LIRAGLUTIDE IN PREPARATION OF DRUG FOR TREATING ACUTE AND CHRONIC TRANSPLANT REJECTION
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/042391 International Application No.: PCT/CN2018/103447
Publication Date: 07.03.2019 International Filing Date: 31.08.2018
IPC:
A61K 38/26 (2006.01) ,A61P 37/06 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
22
Hormones
26
Glucagons
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
02
Immunomodulators
06
Immunosuppressants, e.g. drugs for graft rejection
Applicants:
华中科技大学同济医学院附属同济医院 TONGJI HOSPITAL TONGJI MEDICAL COLLEGE HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY [CN/CN]; 中国湖北省武汉市 硚口区解放大道1095号 No. 1095, Jiefang Avenue, Qiaokou District Wuhan, Hubei 430030, CN
Inventors:
杨军 YANG, Jun; CN
王志敏 WANG, Zhimin; CN
马东霞 MA, Dongxia; CN
舒砚文 SHU, Yanwen; CN
李亚坤 LI, Yakun; CN
胡小凡 HU, Xiaofan; CN
王梦君 WANG, Mengjun; CN
李尚林 LI, Shanglin; CN
Agent:
武汉开元知识产权代理有限公司 WUHAN KAIYUAN INTELLECTUAL PROPERTY AGENT LTD.; 中国湖北省武汉市 江岸区香港路145号远洋大厦14层 14th Floor, Yuanyang Building No. 145, Xianggang Road, Jiang'an District Wuhan, Hubei 430015, CN
Priority Data:
201710775037.531.08.2017CN
Title (EN) APPLICATION OF LIRAGLUTIDE IN PREPARATION OF DRUG FOR TREATING ACUTE AND CHRONIC TRANSPLANT REJECTION
(FR) APPLICATION DU LIRAGLUTIDE DANS LA PRÉPARATION D’UN MÉDICAMENT POUR TRAITER UN REJET DE GREFFE AIGU ET CHRONIQUE
(ZH) 利拉鲁肽在制备治疗急慢性移植排斥反应药物中的应用
Abstract:
(EN) An application of liraglutide in preparation of a drug for treating acute and chronic transplant rejection. The graft in the acute and chronic transplant rejection is the heart, lung, or kidney. The drug is a drug administered by subcutaneous injection. The dosage of liraglutide is 75 μg/kg-300 μg/kg, and liraglutide is administered twice a day. Liraglutide can prolong the survival time of a transplant recipient by reducing the activity of effector T cells, lower the expression of adhesion molecules, inhibit inflammatory infiltration, and inhibit transformation from endothelium to mesenchyme. Thus, the graft vasculopathy is alleviated and the fibrosis progression after transplantation is slowed.
(FR) La présente invention concerne une application du liraglutide dans la préparation d’un médicament pour traiter un rejet de greffe aigu et chronique. La greffe dans le rejet de greffe aigu et chronique est une greffe de cœur, de poumon ou de rein. Le médicament est un médicament administré par injection sous-cutanée. La dose de liraglutide est de 75 µg/kg à 300 μg/kg, et le liraglutide est administré deux fois par jour. Le liraglutide peut prolonger le temps de survie d’un receveur de greffe par réduction de l’activité des lymphocytes T effecteurs, diminuer l’expression de molécules d’adhésion, inhiber l’infiltration inflammatoire et inhiber la transformation de l’endothélium en mésenchyme. Par conséquent, la vasculopathie du greffon est réduite et la progression d’une fibrose après une transplantation est ralentie.
(ZH) 利拉鲁肽在制备治疗急慢性移植排斥反应药物中的应用。所述急慢性移植排斥反应中的移植物为心脏、肺部或肾脏。所述药物为皮下注射药物。利拉鲁肽的使用剂量为75μg/kg-300μg/kg,每天给药两次。利拉鲁肽能通过降低效应T细胞活性来延长移植受体的存活时间,并且下调黏附分子表达,抑制炎性浸润,抑制内皮向间质转化。从而改善移植物血管病及移植后纤维化进展。
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)